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A B S T R A C T
The challenge in treating the older adult with cancer is accurately accounting for and adapting
management to the heterogeneity in health status of the individual patient. Many oncologists
recognize that chronological age alone should not be the determinant when deciding on a
treatment regimen. Easily measurable markers that provide an assessment of functional age
would be ideal to assess frailty, which may predispose the patient to complications from cancer
treatment, including increased toxicity, functional decline, decreased quality of life, and poorer
survival. Several categories of potential markers, including chronic inflammatory markers, markers
of cellular senescence, and imaging to assess muscle mass to detect sarcopenia, may provide
insight into the likelihood of treatment-related complications. This article discusses candidate
markers and strategies to evaluate these markers in cancer treatment trials, with the aim of
developing a method to assess risk of oncologic outcomes and guide management decisions for
both the physician and patient.
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INTRODUCTION
There is great heterogeneity in the ability of older
adults to tolerate cancer treatment. Older adults are
at risk for increased toxicity from cancer therapy,
but standard methods to accurately determine this
risk are lacking. Clinical factors routinely collected
during the cancer assessment such as age, perfor-
mance status (PS), and comorbidities are not reli-
able predictors of toxicity.1-4 Out of concern for
poor tolerability, chemotherapy is often withheld
from older patients on the basis of age alone, despite
evidence that some older adults can derive benefit
from treatment similar to that derived by younger
patients.4,5 As a result, older adults with cancer are
often undertreated, make up a minority of patients
enrolled onto clinical trials,6 and are not gaining the
benefits of cancer therapeutic advances as much as
younger patients.7
To individualize treatment for the older pa-
tient, more data are needed beyond their chrono-
logic age and comorbidities. An accurate sense of
their functional age with more objective measures
that are easily measured, easily reproduced, and pre-
dictive of outcome are needed. Some consider frailty
a reflection of functional age because it gives a mea-
sure of physiological age not necessarily in propor-
tion to chronological age.8 Frailty can be defined as
the inability of an individual to return to their base-
line physical status after an insult to the body, or a
measure of resilience. Fried et al9 described a pheno-
type of frailty as having three of the following: 10-
pound unintentional weight loss, poor grip strength,
exhaustion, slow gait, and low physical activity level.
The degree of resilience varies among older individ-
uals as commonly seen by the differing degrees to
which older patients tolerate treatment in terms of
adverse effects.
The ideal marker would reflect the degree of a
patient’s functional reserve and predict tolerance to
cancer treatment. Some measures of this already
exist. The comprehensive geriatric assessment can
assess multiple aspects of a patient’s life, including
physical function, physical and mental health, cog-
nition, and socioeconomic circumstances. The ap-
plication of the geriatric assessment in oncology is
discussed elsewhere in this issue. But, likely because
of lack of time, resources, and expertise, the compre-
hensive geriatric assessment is not widely used in
clinical practice. In addition, one could imagine that
it may be difficult to measure repeatedly in patients
who are likely fatigued from the cancer treatment
itself. There are several proposed biologic markers of
aging with various amounts of data on their ability
to correlate with physical function or predict func-
tional decline and/or mortality. Another largely un-
explored area is the use of imaging studies for
assessment of the ratio of muscle mass or fat to
muscle. This assessment could be done on com-
puted tomography scans commonly used for tumor
staging evaluations that could potentially give more
information on functional reserve and/or predict a
decline in physical function.
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This review will discuss potential markers of functional age to
complement clinical geriatric assessment as well as their potential
incorporation into clinical trials to assess their value. Validation will be
necessary before any marker can be routinely used in practice to better
inform patients and physicians of the potential harms and/or risks
associated with treatment and to guide clinical management decisions.
A summary of the proposed markers is listed in Table 1.
POTENTIAL BIOMARKERS THAT WARRANT FURTHER STUDY
Markers of Systemic Inflammation
Markers of chronic inflammation are potential biomarkers of
frailty and functional reserve that have been studied most in terms of
their correlation with clinical measures of frailty, functional decline,
and mortality. Prothrombotic factors have also been noted to be
increased with chronic inflammatory markers, likely because of a
costimulatory effect between the two processes. For instance, inflam-
matory cytokines such as tumor necrosis factor  (TNF-) and
interleukin-6 (IL-6) can stimulate production of prothrombotic fac-
tors such as plasminogen activator inhibitor-1 (PAI-1) and fibrino-
gen.32 The synthesis of cytokines IL-1B, IL-6, and PAI-1 is also
induced by D-dimer, a marker of the activated coagulation system 33
Likewise, when vascular cell adhesion molecule (VCAM) is exposed to
inflammatory markers TNF- and IL-1B, it is cleaved to soluble vas-
cular cell adhesion molecule (sVCAM), which has been shown to be
increased in patients with age-related diseases such as rheumatoid
arthritis.34 For the purpose of this discussion, markers of the coagula-
tion system such as D-dimer and sVCAM will be included with
chronic inflammatory markers. In general, proinflammatory media-
tors such as IL-6, TNF-, D-dimer, and PAI-1, increase with age, even
among healthy individuals.36-38 These markers are proposed to accelerate
the aging process and exacerbate multiple age-related diseases.39-41
Multiple studies have shown that these markers correlate with
clinical measures of frailty and are increased to a greater degree in frail
patients than in age-matched, nonfrail controls.10-14,42,43 One study of
110 patients older than age 75 years evaluated a combination of in-
flammatory markers (TNF-, IL-6, C-reactive protein [CRP]) and
low albumin and their relationship to several different clinical mea-
sures of frailty.12 The degree of clinical frailty independently correlated
with increased inflammatory marker levels and lower albumin levels,
adjusting for multiple factors, including age, sex, body mass index,
smoking status, number of comorbidities, and number of medica-
tions. Therefore, these markers might be useful as a quick measure of
the patient’s degree of frailty or biologic age and might provide insight
into an individual’s tolerance to cancer treatment.
Decline in physical function and loss of independence is of
great concern for older adults undergoing cancer treatment, and
several studies in the general geriatric population have shown that
increased chronic inflammatory and procoagulant markers predict
functional decline.15-19,45,46 In an analysis of moderately to severely
disabled women age 65 years and older on the Women’s Health
and Aging Study, higher baseline IL-6 levels were associated with
significantly higher levels of functional decline, including de-
creased mobility, activities of daily living deficits, increased walk-
ing limitations, and decreased walking speed, compared with
women with lower IL-6 levels.46 Elevated inflammatory cytokines
and procoagulant marker levels also correlate with postoperative
complications and functional decline after oncologic surgery.16,20
Whether chronic inflammatory markers can independently pre-
dict functional decline associated with cancer treatment warrants
further study.
Elevated inflammatory markers are also associated with mortal-
ity risk in the elderly.15,17,19,44 In a study of community dwelling adults
(mean age, 78 years), higher levels of sVCAM were independently








Serum or plasma ELISA Yes (CRP, IL-6, TNF-,
D-dimer, IL-1RA)













Telomere length Leukocyte DNA q-PCR or Southern
blot




p16INK4a T-lymphocyte RNA qRT-PCR No No Krishnamurthy et al25
Liu et al26
Song et al27
Sarcopenia CT scan Commercially available
software for body
composition analysis




Abbreviations: CRP, C-reactive protein; CT, computed tomography; ELISA, enzyme-linked immunosorbent assay; IL-6, interleukin-6; IL-1RA, IL-1 receptor
antagonist; q-PCR, quantitative polymerase chain reaction; qRT-PCR, quantitative real-time PCR; sVCAM, soluble vascular cell adhesion molecule; TNF-, tumor
necrosis factor-.
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associated with poorer baseline functional status and mortality at 4
years (hazard ratio, 1.2; P  .002).17 Higher sVCAM, D-dimer, and
IL-6 were independently related to 4-year mortality, adjusting for
functional status, demographics, and comorbidities.
Several chronic inflammatory markers, (IL-6, D-dimer, and
CRP) also have the ability to predict both decline in function and
mortality, even after controlling for age, comorbidities, and physical
function,15,19,42 and may have greater predictive ability among pa-
tients without baseline functional impairments, suggesting they may
identify prefrail patients that may not otherwise have been identified
without extensive geriatric assessment testing. The majority of studies
evaluating chronic inflammatory markers in the general geriatric pop-
ulation are mainly epidemiologic observations. The role of these
markers in the management of general geriatric patients is being
studied in ongoing geriatric research.
The direct link between increased inflammatory markers and
functional decline has not been established. It has been postulated
that interconnections between inflammatory cytokines and the
CNS, endocrine systems, and musculoskeletal system could result in
sarcopenia and/or bone loss leading to decreases in function. Several
animal model studies suggest a role in the catabolic effects contrib-
uting to muscle wasting,47-49 but whether this is a direct effect of
the inflammatory markers or mediated by other circulating factors
remains unknown.
The benefits of using chronic inflammatory markers include the
ease of measurement. They can be collected during blood draws rou-
tinely done for cancer management. They can be measured with
enzyme-linked immunosorbent assays, and a panel of inflammatory
markers can be included in a multiplex enzyme-linked immunosor-
bent assay. The problem with assessing chronic inflammatory markers
is that they reflect and may be produced by the cancer itself. Experts in
the biomarkers of aging development process have recommended
that “. . . an aging marker should both correlate with functional age
but also be independent from specific pathologic conditions.”50 Al-
though chronic inflammatory markers may not technically be true
aging biomarkers, they are potentially useful in reflecting correlated
processes that may predict oncologic outcomes.
An argument for measuring cytokines in the setting of an ongo-
ing malignancy is that they are associated with poorer PS and quality of
life (QOL), as well as higher levels of fatigue,51,52 that may affect a
patient’s ability to tolerate treatment. There is evidence that cytokine
levels may provide prognostic information beyond PS. In a study of
377 patients with acute myeloid leukemia, cytokine expression (IL-6,
IL-1, IL-2, TNF-, and CRP) was evaluated in 58 patients identified at
the extremes of survival (median survival, 4.9 months and 46.3
months in patients with poor and good prognosis, respectively).53
There was no statistically significant difference in survival when
evaluated by PS (Eastern Cooperative Oncology Group 0 to 1 v 2).
However, when categorized by cytokine expression levels (low, inter-
mediate, high) and PS, there was a large difference in survival between
low-, intermediate-, and high-risk groups (56.1 months, 9.85 months,
and 8.35 months, respectively; P  .02).
Markers of Cellular Senescence
If a cell does not enter the apoptotic pathway in response to DNA
damage, the cell can activate a DNA damage response pathway leading
to permanent cell cycle arrest termed cellular senescence.54,55 Cellular
senescence, a term for the mitotic arrest of a cell, is induced by DNA
damage through several mechanisms, including cell division and sub-
sequent telomere shortening, as well as forms of cellular stress, includ-
ing activation of oncogenes and oxidative stress.55 The assumption is
that as a person ages, one accumulates more and more senescent cells.
There may be a connection between senescent cells and the in-
creasing levels of chronic inflammatory markers seen in older individ-
uals. Cellular division has ceased in senescent cells, but they actively
secrete proinflammatory proteins collectively known as the
senescence-associated secretory phenotype (SASP).56 SASP factors are
proposed to increase inflammation in surrounding tissues and in the
circulation and contribute to the aging process. Factors within the
SASP are similar to the inflammatory and coagulation markers asso-
ciated with frailty and mortality in the elderly population.44,57
Because there are no established circulating markers of cellular
senescence, markers associated with senescence, including telomere
length and p16INK4a, have been explored as potential biologic markers
of aging.
Telomere length. Telomeres are proteins at the ends of chromo-
somes that shorten with each cell division, eventually leading to mi-
totic arrest termed “replicative senescence,” which has been proposed
to contribute to the aging process.58 Because telomere length decreases
with increasing age, telomere length has been evaluated as a biomarker
of aging. In a study of 143 patients older than 60 years, Cawthon et al21
demonstrated a correlation between shorter telomere length by age
and increased mortality. Since that time, multiple studies have at-
tempted to replicate this finding with varying results, but because of
the correlation with aging as well as age-related disease, telomere
length continues to be a marker of interest in the search for markers of
biologic age.59
Interestingly, telomere length may also have a role in predict-
ing cancer prognosis. Shorter telomere length has been associated
with poorer prognosis among patients in retrospective studies of
colorectal cancer, soft tissue sarcomas, breast cancer, and lung can-
cer.60 Other studies on the association between telomere length and
cancer-related mortality have yielded conflicting results. Telomere
length has also been associated with functional status or mortality in
several studies.21,22-24
Telomere length can be measured in peripheral blood leukocytes
under the presumption that it represents telomere length in other
tissues. This marker could be obtained in conjunction with routine
blood draws, but it requires laboratory methods that have technical
limitations. Telomere length can be measured by estimating the size of
cleaved telomere fragments (by using the terminal restriction frag-
ment method61), shortest telomere length by fluorescent in situ hy-
bridization, or by quantitative real-time polymerase chain reaction.59
A potential disadvantage to using telomere length as a biomarker is
that it could be affected by many processes other than age, including
genetic factors, environmental exposure, and dietary intake.59 As with
chronic inflammatory markers, a correlation of frailty and telomere
length may be important for predicting outcomes of interest, regard-
less of whether it is considered a pure aging biomarker.
Dysfunctional telomeres. Dysfunctional telomeres may also have
a role as biomarkers of aging. In a preclinical study, Jiang et al62
identified markers secreted by bone marrow cells with telomere dys-
function (stathmin, CRAMP, EF1, and chitinase 3). These markers
were found to distinguish old from young adults and healthy older
adults versus older adults with age-related diseases. The benefit to
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these markers is that they can be detected in the serum, making their
measurement much easier than assessments of telomere length.
p16INK4a. The activation of oncogenes or the loss of tumor
suppressor function can also induce senescence, primarily controlled
by the p53 pathway and its downstream mediators.63,64 p16INK4a is
involved in an alternate pathway involved in permanent cell-cycle
arrest that is now recognized as a marker of cellular senescence in
animal models.25 It has been demonstrated that p16INK4a levels in-
crease with age in mammalian models and humans, and its expression
has also been correlated with higher levels of IL-6.25-27
The role of p16 levels in the geriatric oncology population is
currently being evaluated in an ongoing clinical trial (NCT00849758).
Interestingly, p16INK4a levels have recently been found to increase in
patients receiving chemotherapy for breast cancer, making this a po-
tential marker for studying the effects of chemotherapy on the aging
process.65 Levels of p16INK4a can be obtained from the blood via
quantitative real-time polymerase chain reaction on T-lymphocyte
RNA, although the assay is complicated and not generally available at
this time.60
Imaging for Sarcopenia
Another modality of evaluation that may predict underlying
frailty and/or functional age is imaging for sarcopenia. Sarcopenia can
be defined as muscle mass two standard deviations below that of a
healthy adult.66 Sarcopenia is more prevalent in older adults and is a
hallmark of frailty and subsequent disability.67 In addition, circulating
inflammatory mediators likely contribute to the development and
progression of sarcopenia.68,69
Beyond sarcopenia, there is currently major interest in body
composition and how it correlates with sarcopenia; for example, obese
patients can have a decrease in muscle mass termed sarcopenic obe-
sity. A study of 250 patients with body mass index more than 30
evaluated muscle mass by using whole-body dual-energy x-ray ab-
sorptiometry and computed tomography scans.70 Patients with sar-
copenic obesity had poorer response to chemotherapy, poorer PS, and
a 10-month decrement in median survival after adjusting for standard
predictors of cancer-related mortality.
The advantages to using radiographic technology to assess for
sarcopenia is that this information could be collected at the time of
routine imaging studies done for tumor evaluation and/or restaging.71
Sarcopenia may be present before the onset of disability,67 and sar-
copenia may be disguised by obesity. Therefore, imaging studies for
sarcopenia may identify the prefrail or frail patient who otherwise may
not have been detected. There is also evidence that body composition
may be related to toxicity from cytotoxic chemotherapy.72 A disad-
vantage of imaging evaluation for sarcopenia is the cost of the com-
puterized imaging technology and the expertise required to calculate
the degree of muscle mass in each patient. It is uncertain whether
radiographic evaluation for sarcopenia will add more to geriatric
assessment than standard measures such as grip strength and timed
up and go. One possibility would be to use the aforementioned
measures as a screening tool, which might prompt further evalua-
tion for sarcopenia.
Other Potential Aging Markers
There are other aging biomarker candidates that may prove to be
helpful predictors of oncologic outcomes. These include genes associ-
ated with longevity, single nucleotide polymorphisms associated with
aging, lymphopenia, and oxidative stress markers.50,60 Data for these
potential markers in relation to clinical measures of frailty and mor-
tality prediction is currently scant, but future studies may provide
more insight into their use in geriatric oncology.
MOVING FORWARD: INCORPORATING BIOMARKERS INTO
ONCOLOGY CLINICAL TRIALS
The need for more accurate assessment of the functional age of pa-
tients with older cancer is clear, and clinical trials are beginning to
incorporate some of the aforementioned markers. The European Or-
ganisation for Research and Treatment of Cancer is including collec-
tion of aging biomarkers such as markers of chronic inflammation,
aging genes, and markers of cellular senescence in patients enrolled
onto clinical trials. The ideal biomarker of functional age or frailty
would provide additional information beyond what is collected dur-
ing routine oncology evaluation and would be easily measured and
easily repeated throughout treatment without causing increased bur-
den to the patient.
When evaluating potential biomarkers in clinical trials, we need
end points that will accurately predict treatment tolerance and out-
comes. Outcomes should include the development of adverse events,
functional decline, QOL, and survival, which would enable patients to
make better-informed decisions regarding their treatment. Such
markers would also help clinicians identify the most appropriate treat-
ment regimen for the patient (ie, full-dose chemotherapy, modified
doses, best supportive care) as well as identify patients in need of
additional supportive care during treatment.
When assessing biomarkers in the context of cancer and cancer
treatment, it will be important to assess the biomarkers at various time
points to evaluate the impact of aging markers at different time points
in the cancer evaluation and treatment trajectory. The measurement of
biomarkers over time could be used to address four important questions.
First, how much does tumor burden and treatment (recent
surgery, radiation therapy, and chemotherapy) affect the physical
function (degree of frailty) for the individual patient? Starting with
adjuvant therapy trials will likely remove the confounding factor of the
underlying malignant process contributing to the biomarker levels
and potentially clinical measures of frailty and QOL. Consider mea-
suring markers before tumor removal, and at various time points after
surgery because surgery itself would be expected to temporarily elevate
these markers and contribute to a temporary decline in physical func-
tion, depending on the impact of the surgery on the individual patient.
The most appropriate time point after surgery to measure biomarkers
is not known, but circulating acute phase reactants from the surgery
itself should be resolved by 6 to 8 weeks after surgery.73,74
Second, do the increased circulating markers correlate with clin-
ical measures of frailty? And if so, even if the increased biomarkers
were the result of the underlying tumor burden, will they still have an
impact on treatment tolerance? Will they decrease with treatment or
increase? If they decrease, would this improve treatment tolerance to
the point that the dose of chemotherapeutic drugs in the regimen
could potentially be increased?
Third, will chemotherapy and/or radiation therapy contribute to
an increase in senescent cell burden? There are suggestions that chem-
otherapy contributes to the development of cellular senescence.
Would this result in an increase in circulating SASP factors and con-
tribute to a decline in physical function or health-related QOL greater
Hubbard, Cohen, and Muss
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than that for a patient who had not received chemotherapy? Could a
resulting increase in SASP factors contribute to accelerated aging? In
studies done on survivors of childhood cancers, investigators have
found an increase in age-related pathologies such as atherosclerotic
disease.75,76 Is this a result of the development of senescent cells in
response to treatment resulting in premature aging?
Fourth, if senescent cells contribute to local tissue inflammation
(destruction?) resulting in changes such as epithelial to mesenchymal
transition, would this result in decreased disease-free survival,
progression-free survival, or overall survival?
Future Directions
In the development of biomarkers, it is anticipated that there will
be a combination or panel of markers that will have the best predictive
power of end points such as toxicity, functional decline, QOL, and
survival. As with the geriatric assessment, patients would potentially
be placed into frailty and/or aging categories (ie, low-, intermediate-,
or high-risk groups) to predict risk for the specific end point. This
panel of markers should then be validated in older patients enrolled
onto clinical trials. If validated, the panel could then be evaluated as a
decision tool in a prospective trial, which could be used to stratify
patients and assign them into different management categories such as
modified treatment regimens.
Ultimately, research on biomarkers of aging may provide us with
more accurate assessments of risk and may also identify biologic
targets for interventions to ease the burden of cancer treatment for
older patients. Future studies using a biomarker of aging panel could
be incorporated into interventional studies to assess whether interven-
tions in patients identified as at risk for poorer outcomes (toxicity or
decreased survival or decline in physical function) can be modified or
prevented by focused interventions. Potential interventions could in-
clude pharmacologic agents targeting cachexia/sarcopenia, chronic
inflammation, and/or the burden of senescent cells. Other interven-
tions may include physical rehabilitation, nutritional supplementa-
tion, or psychosocial methods.
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